Amphastar Pharmaceuticals ROA 2012-2024 | AMPH
Current and historical return on assets (ROA) values for Amphastar Pharmaceuticals (AMPH) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Amphastar Pharmaceuticals ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2024-09-30 |
$0.16B |
$1.55B |
10.25% |
| 2024-06-30 |
$0.17B |
$1.49B |
10.84% |
| 2024-03-31 |
$0.15B |
$1.57B |
10.25% |
| 2023-12-31 |
$0.14B |
$1.51B |
10.52% |
| 2023-09-30 |
$0.14B |
$1.55B |
12.16% |
| 2023-06-30 |
$0.10B |
$1.38B |
11.27% |
| 2023-03-31 |
$0.09B |
$0.77B |
12.54% |
| 2022-12-31 |
$0.09B |
$0.74B |
12.51% |
| 2022-09-30 |
$0.08B |
$0.73B |
10.85% |
| 2022-06-30 |
$0.09B |
$0.72B |
13.17% |
| 2022-03-31 |
$0.08B |
$0.72B |
12.12% |
| 2021-12-31 |
$0.06B |
$0.67B |
9.56% |
| 2021-09-30 |
$0.04B |
$0.65B |
5.70% |
| 2021-06-30 |
$0.01B |
$0.67B |
1.72% |
| 2021-03-31 |
$0.00B |
$0.65B |
0.48% |
| 2020-12-31 |
$0.00B |
$0.63B |
0.33% |
| 2020-09-30 |
$0.01B |
$0.61B |
1.18% |
| 2020-06-30 |
$0.00B |
$0.60B |
0.68% |
| 2020-03-31 |
$0.05B |
$0.57B |
8.86% |
| 2019-12-31 |
$0.05B |
$0.59B |
8.45% |
| 2019-09-30 |
$0.05B |
$0.59B |
9.26% |
| 2019-06-30 |
$0.05B |
$0.60B |
9.90% |
| 2019-03-31 |
$0.00B |
$0.55B |
0.40% |
| 2018-12-31 |
$-0.01B |
$0.51B |
-1.27% |
| 2018-09-30 |
$-0.01B |
$0.48B |
-1.53% |
| 2018-06-30 |
$-0.01B |
$0.45B |
-2.01% |
| 2018-03-31 |
$-0.00B |
$0.45B |
-0.90% |
| 2017-12-31 |
$0.00B |
$0.45B |
0.90% |
| 2017-09-30 |
$0.00B |
$0.44B |
0.00% |
| 2017-06-30 |
$0.00B |
$0.44B |
0.92% |
| 2017-03-31 |
$0.01B |
$0.44B |
2.12% |
| 2016-12-31 |
$0.01B |
$0.43B |
2.41% |
| 2016-09-30 |
$0.02B |
$0.43B |
5.18% |
| 2016-06-30 |
$0.01B |
$0.41B |
3.52% |
| 2016-03-31 |
$0.00B |
$0.40B |
0.00% |
| 2015-12-31 |
$-0.00B |
$0.39B |
-0.76% |
| 2015-09-30 |
$-0.01B |
$0.40B |
-3.54% |
| 2015-06-30 |
$-0.02B |
$0.40B |
-4.04% |
| 2015-03-31 |
$-0.01B |
$0.40B |
-2.53% |
| 2014-12-31 |
$-0.01B |
$0.39B |
-2.87% |
| 2014-09-30 |
$-0.01B |
$0.40B |
-1.62% |
| 2014-06-30 |
$-0.00B |
$0.40B |
-0.37% |
| 2014-03-31 |
$0.01B |
$0.35B |
4.68% |
| 2013-12-31 |
$0.01B |
$0.34B |
14.16% |
| 2013-09-30 |
$0.01B |
$0.00B |
17.67% |
| 2013-06-30 |
$0.02B |
$0.00B |
21.45% |
| 2013-03-31 |
$0.01B |
$0.00B |
17.67% |
| 2012-12-31 |
$0.02B |
$0.32B |
22.71% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.840B |
$0.644B |
|
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
|
